| scholarly article | Q13442814 |
| P50 | author | Amit Mahipal | Q79225628 |
| P2093 | author name string | Jae Lee | |
| Nancy Burke | |||
| Richard D Kim | |||
| Gregory M Springett | |||
| Tzu-Hua Juan | |||
| Jonathan R Strosberg | |||
| Dan M Sullivan | |||
| Aaron Denson | |||
| Barbara Bertels | |||
| Georgine Wapinsky | |||
| P2860 | cites work | Prognostic indices for older adults: a systematic review | Q26865698 |
| Toxicity and response criteria of the Eastern Cooperative Oncology Group | Q29619399 | ||
| Preoperative leukocytosis, anemia and thrombocytosis are associated with poor survival in non-small cell lung cancer. | Q33385363 | ||
| Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapy | Q33601715 | ||
| Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience | Q34252383 | ||
| The 2030 problem: caring for aging baby boomers | Q34623257 | ||
| Prevalence of hyponatremia and association with mortality: results from NHANES | Q34657781 | ||
| Participation and survival of geriatric patients in Phase I clinical trials: the Karmanos Cancer Institute (KCI) experience | Q34801461 | ||
| Clinical trial design for target-based therapy | Q34981120 | ||
| Never too old? Age should not be a barrier to enrollment in cancer clinical trials | Q36081341 | ||
| Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience | Q36510136 | ||
| Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. | Q37016543 | ||
| Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience | Q37417441 | ||
| Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors | Q39605793 | ||
| Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment | Q43043839 | ||
| Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center | Q43455943 | ||
| Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience | Q43522124 | ||
| Hyponatremia as prognostic factor in small cell lung cancer--a retrospective single institution analysis. | Q44484991 | ||
| Preoperative anemia, leukocytosis and thrombocytosis identify aggressive endometrial carcinomas | Q45184398 | ||
| Elevated white blood cell count at the time of recurrence diagnosis is an indicator of short survival in patients with recurrent cervical cancer | Q45231806 | ||
| Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes | Q45810450 | ||
| Prospective validation of a prognostic score to improve patient selection for oncology phase I trials | Q46068560 | ||
| Phase I clinical trial design in cancer drug development | Q47687409 | ||
| Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials | Q50120629 | ||
| Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma | Q62392158 | ||
| Critical role of phase I clinical trials in cancer treatment. American Society of Clinical Oncology | Q73117425 | ||
| Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials | Q73668726 | ||
| 90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial? | Q81447150 | ||
| The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: a retrospective cohort study | Q87123309 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phase I clinical trial | Q5452194 |
| P304 | page(s) | 133-139 | |
| P577 | publication date | 2018-02-01 | |
| P1433 | published in | American Journal of Clinical Oncology | Q2886177 |
| P1476 | title | Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials | |
| P478 | volume | 41 |
| Q42046541 | Academic Cancer Center Phase I Program Development |
| Q92249212 | Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multi-Tumor Associated Antigen Specific Cytotoxic T Lymphocytes: A Phase I Study |
| Q57471266 | Survival outcome and prognostic model of patients with colorectal cancer on phase 1 trials |
Search more.